make a crypto- Top Block

Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.Xia Yiping, CEO of Extreme Vietnam: I won't run away! Agreeing with employees' reasonable demands, communication with Baidu and Geely working groups has been established. The reporter learned from the inside of Extreme Yue Automobile that on the evening of December 12, Xia Yiping, CEO of Extreme Yue Automobile, informed all employees of the latest progress by means of synchronous news of flying books. Xia Yiping said: "Shanghai, the social security provident fund tax payment is completed; Beijing Jidu Technology has paid the provident fund before, because the system can't pay the social security tax tonight (December 12), and will go to the counter to pay it early tomorrow (December 13); Beijing jidu service, social security provident fund tax payment is completed; Wuhan, the social security provident fund tax payment is completed; Zhejiang, the provident fund has been paid before, and the social security tax will be paid tomorrow (December 13); In the remaining cities, the social security provident fund has been paid, and the individual tax will be paid tomorrow (December 13). " (national business daily)According to the local government, Russia attacked the energy facilities in the Lviv region in western Ukraine.

Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.Stock index futures continued to fall, and the main contract of SSE 50 Stock Index Futures (IH) fell by 2.00% in the day, and now it is reported at 2,653.6 points. The main contract of CSI 500 stock index futures (IC) fell by 2.00% in the day and is now reported at 5976.8 points.According to TASS news agency, Turkish President Erdogan said that if national security is threatened, Turkey will take action against Syrian terrorists.

On the 13th, the European futures of the container freight index rose by 7.03%, and the latest main contract positions changed as follows. According to the data of the exchange, as of December 13th, the European futures of the main contract container freight index closed at 2502, up or down by +7.03%, with a turnover of 41,900 lots. The position data showed that the top 20 seats were net, and the difference position was 3,022 lots. A total of 78,900 lots of European futures contracts were traded, an increase of 8,599 lots over the previous day. The first 20 seats in the contract held 25,100 lots, an increase of 466 lots over the previous day. The short positions in the top 20 seats of the contract were 22,100 lots, a decrease of 120 lots from the previous day. (Sina Futures)The head of the region said that the Russian attack on the key infrastructure in the Ivano-Frankov region was the biggest attack on the region so far.Yingli shares: Yingli shares increased capital by 80 million yuan to its holding subsidiary. Yingli shares announced that the company and Shanghai Moqin Intelligent Technology Co., Ltd. increased capital to Nanchang Yingli Precision Manufacturing Co., Ltd., with a total capital increase of 80 million yuan, of which Yingli shares increased capital by 67 million yuan in cash and Shanghai Moqin increased capital by 13 million yuan in cash. After this capital increase, the registered capital of Nanchang Yingli will increase from 20 million yuan to 100 million yuan. After the capital increase is completed, Yingli shares hold 80% of the shares of Nanchang Yingli and Shanghai Moqin holds 20% of the shares. This capital increase does not constitute a connected transaction and does not need to be submitted to the company's shareholders' meeting for consideration.